Paul Feuerstadt, MD, FACG, AGAF, discusses how the management of recurrent Clostridioides difficile infections is evolving toward more targeted approaches, including microbiome-based therapies like ...

Research by the University of Plymouth showed spores of Clostridium difficile, commonly known as C. diff, are completely unaffected despite being treated with high concentrations of bleach used in ...

The world-renowned infectious disease researcher was profiled in The New York Times for his role in developing Dificid, the first new medicine in 25 years approved to treat diarrhea caused by ...

The panelist discusses Vowst, an FDA-approved live microbiota therapeutic that works by introducing healthy donor-derived gut ...

Antibiotic-associated diarrhea (AAD) and Clostridium difficile disease (CDD) are common conditions linked to the use of antibiotics. Studies evaluating the efficacy of probiotics for the treatment ...

Purpose The pharmacology, clinical efficacy, safety, dosage and administration, and place in therapy of fidaxomicin for the treatment of Clostridium difficile infection (CDI) are reviewed.

cell culture and humanized disease models. These studies have found that gut astrocytes are important regulators of mucosal barrier function and inflammation in inflammatory bowel disease, necrotizing ...